-

02:13:44 PM

VIRI Stock News

VIRI - Virios Therapeutics Inc

09/18/23 7:05 AM

Nasdaq : VIRI

low float

Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia and Long-COVID, today announced that it

RHEA-AI

neutral

09/12/23 7:05 AM

Nasdaq : VIRI

conferenceslow float

Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023

Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“FM”) and Long-COVID (“LC”), announced today

RHEA-AI

neutral

08/14/23 7:05 AM

Nasdaq : VIRI

low float

Virios Therapeutics Announces Halt to At-The-Market Offering Sales

Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“FM”) and Long-COVID, today announced that it

RHEA-AI

neutral

08/10/23 7:05 AM

Nasdaq : VIRI

earningslow float

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral

RHEA-AI

neutral

08/09/23 7:05 AM

Nasdaq : VIRI

clinical triallow float

Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia

Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“FM”) and Long-COVID, today announced that the

RHEA-AI

neutral

08/03/23 4:05 PM

Nasdaq : VIRI

conferencesearningslow float

Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID,

RHEA-AI

neutral

07/17/23 7:05 AM

Nasdaq : VIRI

covid-19low float

Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced that female patients

RHEA-AI

neutral

05/25/23 4:05 PM

Nasdaq : VIRI

low float

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a clinical‐stage biopharmaceutical company, today announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Below are some

RHEA-AI

positive

05/15/23 7:05 AM

Nasdaq : VIRI

clinical triallow float

Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia

Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced that it has submitted

RHEA-AI

very positive

05/11/23 7:05 AM

Nasdaq : VIRI

earningslow float

Virios Therapeutics Announces First Quarter 2023 Financial Results

Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced financial results for

RHEA-AI

neutral

1 2 3 4 5 6 7 Next